GlassScriptPhysician profile
Aaron Freeman
NPI 1710417829
$1,716.91
in general payments reported to CMS, 2019-2025
29 companies · $37.15 in 2025
The $37.15 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $105 · 2023: $616 · 2024: $959 · 2025: $37.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,611.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $218.63 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $187.61 | 2023-2024 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $166.06 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $160.92 | 2023-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $102.38 | 2023-2024 | Cologuard Collection Kit |
| Amgen INC. | $100.08 | 2023-2024 | Otezla, Repatha, Prolia |
| Abbvie INC. | $90.60 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $67.44 | 2022-2024 | |
| Abbott Laboratories | $64.36 | 2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Alkermes, INC. | $63.89 | 2023 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $59.70 | 2023-2024 | Xarelto |
| Horizon Therapeutics Plc | $51.02 | 2023 | Krystexxa |
| Vanda Pharmaceuticals INC. | $45.71 | 2023 | Hetlioz, Fanapt |
| Phathom Pharmaceuticals, INC. | $43.92 | 2024 | Voquezna |
| Neurocrine Biosciences, INC. | $36.55 | 2024 | Ingrezza |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $23.38 | 2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.95 | 2023 | |
| Shield Therapeutics INC | $21.89 | 2024 | |
| Supernus Pharmaceuticals, INC. | $20.20 | 2023 | Qelbree |
| Pfizer INC. | $18.74 | 2025 | |
| Corium, LLC | $18.68 | 2024 | Azstarys |
| Sanofi-Aventis U.S. LLC | $18.41 | 2025 | |
| Alnylam Pharmaceuticals INC. | $18.41 | 2023 | Amvuttra |
| Dexcom, INC. | $17.21 | 2024 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.08 | 2024 | Xifaxan |
| Axsome Therapeutics, INC. | $16.06 | 2023 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $15.83 | 2024 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $14.64 | 2024 | Eliquis |
| Phadia US INC. | $14.56 | 2024 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.